Largest Venture Capital Investments in Biotechnology Sector During July 2025
Record-Breaking Biotech Funding in July 2025
July 2025 saw a surge in biotech funding, with a significant number of public and private fundraising rounds. The most notable event was MapLight Therapeutics' series D financing, which raised an impressive $372.5 million, making it the largest private funding round of the month.
MapLight Therapeutics, based in Redwood City, California, intends to use the proceeds to advance ML-007C-MA, their lead program targeting schizophrenia and Alzheimer’s disease psychosis, through ongoing phase 2 trials. The financing was co-led by Forbion and Goldman Sachs’ Life Sciences unit, with participation from Sanofi and others.
Another significant private round was secured by Artbio, a radiopharmaceutical company, in a series B round worth $132 million. This funding will support the advancement of AB001, Artbio's lead asset, for the treatment of metastatic castration-resistant prostate cancer, through phase 2 development and the expansion of manufacturing capabilities.
In the public sector, TCG Labs Soleil, a venture builder for biotech startups, raised a substantial $400 million in July 2025. This is part of a larger total raise of $800 million since 2024, aimed at cancer, immunology, and cardiometabolic drug programs spanning locations including San Francisco and Shanghai.
Series D rounds raised the most money in July 2025, with a total of $472.5 million, despite there being only two such rounds. Abivax, a biotech company focused on inflammatory diseases, achieved the biggest funding round overall, closing a $747.5 million public offering. This net proceeds will finance Abivax's operations into the fourth quarter of 2027.
Soleno Therapeutics, another biotech company, raised $200 million in a public fundraising round. They plan to use the net proceeds to fund the commercialization of VYKATTM XR, approved for hyperphagia in individuals with Prader-Willi syndrome.
July 2025 also saw more series B rounds than any other funding type, with four rounds in total. Inflammatory diseases was the subsector that raised the most money in public fundraising, thanks to Abivax's $747.5 million raise.
North America had the highest total private biotech funding in July 2025, with companies headquartered in the region raising $768 million from seven rounds. Europe had the second-highest total private biotech funding, with companies headquartered in Europe raising $173.5 million from two rounds. Asia-Pacific had the third-highest total private biotech funding, with companies headquartered in Asia-Pacific raising $102 million from two rounds.
Overall, public biotech fundraising exceeded the amount raised by private companies for the second month in a row in July 2025. Public biotech fundraising had another impressive month, bringing in a total of $1.898 billion.
[1] Biotech Week. (2025). MapLight Therapeutics Secures $372.5 Million in Series D Financing. [online] Available at: https://biotechweek.com/maplight-therapeutics-secures-372-5-million-in-series-d-financing/
[2] FierceBiotech. (2025). Artbio raises $132M in Series B round to advance AB001 through phase 2. [online] Available at: https://www.fiercebiotech.com/biotech/artbio-raises-132m-in-series-b-round-to-advance-ab001-through-phase-2
[3] Endpoints News. (2025). TCG Labs Soleil raises $400M to back a new crop of biotech startups. [online] Available at: https://endpts.com/tcg-labs-soleil-raises-400m-to-back-a-new-crop-of-biotech-startups/
[4] Endpoints News. (2025). Avalyn Pharma raises $100M in Series D round for pulmonary fibrosis. [online] Available at: https://endpts.com/avalyn-pharma-raises-100m-in-series-d-round-for-pulmonary-fibrosis/
- In July 2025, MapLight Therapeutics, a biotech company specializing in neurological disorders, raised $372.5 million in a series D round, investing in data and cloud computing technology to support the development of ML-007C-MA for schizophrenia and Alzheimer’s disease psychosis.
- Artbio, a radiopharmaceutical company focused on medical-conditions like metastatic castration-resistant prostate cancer, secured a series B round of $132 million for further advancements of their lead asset, AB001, and expanding manufacturing capabilities.
- TCG Labs Soleil, a venture builder for biotech startups, raised an impressive $400 million in July 2025. Their investments in science, including cancer, immunology, and cardiometabolic drug programs, are spread across locations such as San Francisco and Shanghai.
- Soleno Therapeutics, another biotech company, gained $200 million via a public fundraising round to finance the commercialization of VYKATTM XR for Prader-Willi syndrome, a medical-condition characterized by hyperphagia.
